Neurological hospitalizations of patients with a history of past or present malignancy — an observational study from a tertiary neurology center
, 2, 2, 2, 3, 3, 3, 12, 12
Abstract
Introduction. Cancer and its treatment are causing a wide range of neurological complications. Current epidemiological studies on neurological hospitalizations in patients with history of malignancy and active cancer (AC) are lacking. The aim of the study was to assess the numbers and clinical profiles of patients with history of malignancy and AC among patients hospitalized in neurological departments of the University Hospital in Kraków, Poland.
Material and methods. Medical files of all patients who were treated in neurological departments of the University Hospital in Kraków, Poland, from January 2022 to March 2024 were reviewed. Included were patients with a confirmed history of past or present malignancy. The profile of malignancies and reasons for neurological hospitalizations were analyzed.
Results. Among all patients hospitalized in the neurological departments 10.5% had a history of past or present malignancy and 4.9% had AC. The profile of malignancies and reasons for neurological hospitalizations differed among patients with AC and non-active malignancies. In 30.7% of AC the diagnosis of cancer was made (or the diagnostic process started) during hospitalization in the neurological department.
Conclusions. Neurological complications of cancer and its treatment are very common in everyday practice of neurohospitalists and require multidisciplinary care, as well as good cooperation between oncologists and neurologists.
Keywords: cancermalignancyneurological complications of cancerneurooncology
References
- Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3): 229–263.
- Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1): 17–48.
- Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021; 23(8): 1231–1251.
- Zuccato JA, O'Halloran PJ, Zadeh G. A review of , First Edition, 2020. Neurooncol Adv. 2020; 2(1): vdaa102.
- Devine MF, Kothapalli N, Elkhooly M, et al. Paraneoplastic neurological syndromes: clinical presentations and management. Ther Adv Neurol Disord. 2021; 14: 1756286420985323.
- Dardiotis E, Aloizou AM, Markoula S, et al. Cancer-associated stroke: Pathophysiology, detection and management (Review). Int J Oncol. 2019; 54(3): 779–796.
- Gorzelak-Magiera A, Bobola A, Robek A, et al. Selected neurological complications of oncological treatment — literature overview. Oncol Clin Pract. 2023; 19(5): 346–355.
- Lee EQ. Neurologic Complications of Cancer Therapies. Curr Neurol Neurosci Rep. 2021; 21(12): 66.
- Haugh AM, Probasco JC, Johnson DB. Neurologic complications of immune checkpoint inhibitors. Expert Opin Drug Saf. 2020; 19(4): 479–488.
- Zukas AM, Schiff D. Neurological complications of new chemotherapy agents. Neuro Oncol. 2018; 20(1): 24–36.
- Bakouny Z, Yekedüz E, Braun DA, et al. Neurotoxicities of novel non-steroidal anti-androgens for prostate cancer: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2021; 166: 103463.
- Didkowska J, Barańska K, Miklewska M, et al. Cancer incidence and mortality in Poland in 2023. Nowotwory. Journal of Oncology. 2024; 74(2): 75–93.
- Dropcho EJ. Neurologic complications of lung cancer. Handb Clin Neurol. 2014; 119: 335–361.
- Binks S, Uy C, Honnorat J, et al. Paraneoplastic neurological syndromes: a practical approach to diagnosis and management. Pract Neurol. 2022; 22(1): 19–31.
- Haaxma-Reiche H. Neurological complications of leukemia and lymphoma. Handb Clin Neurol. 2012; 105: 711–729.
- Jordan B, Margulies A, Cardoso F, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org, EONS Education Working Group. Electronic address: eons.secretariat@cancernurse.eu, EANO Guideline Committee. Electronic address: office@eano.eu. Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol. 2020; 31(10): 1306–1319.
- Lun R, Siegal D. Cancer-associated ischemic stroke: current knowledge and future directions. Bleeding, Thrombosis and Vascular Biology. 2024; 3(s1).
- Weller M, Stupp R, Wick W. Epilepsy meets cancer: when, why, and what to do about it? Lancet Oncol. 2012; 13(9): e375–e382.
- Singh G, Rees JH, Sander JW. Seizures and epilepsy in oncological practice: causes, course, mechanisms and treatment. J Neurol Neurosurg Psychiatry. 2007; 78(4): 342–349.
- Staff NP, Grisold A, Grisold W, et al. Chemotherapy-induced peripheral neuropathy: A current review. Ann Neurol. 2017; 81(6): 772–781.
- Fink K. Chemotherapy and Anti-Epileptic Drug Interactions. Handbook of Brain Tumor Chemotherapy. 2006: 44–57.
- Bang OhY, Chung JW, Lee MiJi, et al. OASIS-Cancer Study Investigators. Cancer-Related Stroke: An Emerging Subtype of Ischemic Stroke with Unique Pathomechanisms. J Stroke. 2020; 22(1): 1–10.